[101] India [edit] Following the expiration of the semaglutide patent in India in March 2026, several domestic pharmaceutical companies launched generic versions of the drug for the treatment of type 2 diabetes and obesity
As a result, GLP-1 medications are FDA-approved specifically for chronic weight management, and are recommended by major medical organizations as part of a comprehensive weight loss program
Consistent use of the medication, along with a healthy diet and regular exercise, is what leads to long-term success
Instead, contact both your prescribing provider and our eye office promptly so we can assess whether the vision changes require immediate attention or simply closer monitoring while continuing therapy
The Chronos Advantage Customized dosage adjustments based on your progress In-person and virtual follow-ups for continued care Holistic programs that integrate nutrition, exercise, and accountability Transparent, affordable pricing